Moreover, METTL3-mediated PTEN downregulation has shown to affect the important cancer-associated processes [22, 23], the METTL3 and PTEN expression and their correlation in prostate cancer patients were analyzed based on bioinformatic analysis (Fig. S4). This evidence concerns the gene PTEN and prostate carcinoma.